TIROSINT-SOL (levothyroxine sodium) by Pfizer is synthesis. First approved in 2016.
Drug data last refreshed 3h ago · AI intelligence enriched 5d ago
TIROSINT-SOL is an oral liquid formulation of levothyroxine sodium, a synthetic thyroid hormone used to treat hypothyroidism and other thyroid disorders. The drug works by replacing or supplementing endogenous thyroid hormone, with T3 and T4 diffusing into cell nuclei to bind thyroid receptors and activate gene transcription. The liquid formulation offers improved bioavailability and flexibility in dosing compared to tablet formulations.
Product is at peak commercial maturity with modest Part D penetration; brand team size likely stable or optimized for maintenance.
synthesis. Triiodothyronine (T 3 ) and levothyroxine (T 4 ) diffuse into the cell nucleus and bind to thyroid receptor proteins attached to DNA. This hormone nuclear receptor complex activates gene transcription and synthesis of messenger RNA and cytoplasmic proteins. The physiological actions of…
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Bioequivalence of Two Formulations of Levothyroxine Sodium 200 Micrograms (mcg) Under Tablet Form
Levothyroxine Sodium in Thyroidectomized Patients Taking Proton Pump Inhibitors
Study of Dose Adjustment From Levothyroxine to a New Levothyroxine Sodium Test Formulation
Worked on TIROSINT-SOL at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Working on TIROSINT-SOL offers stable, mature-market experience in specialty pharma commercialization with a focus on brand differentiation and patient access in the thyroid hormone market. The zero linked job count suggests this is a smaller or niche brand team, ideal for professionals seeking deep product expertise and close-knit commercial collaboration rather than rapid career scaling.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo